$EVOK
Evoke Pharma Inc

2014 Q1 Form 10-K Financial Statement

#000119312514114409 Filed on March 25, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q4 2013
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.070M $940.0K $1.640M
YoY Change 386.36% 176.47% 95.24%
% of Gross Profit
Research & Development $1.852M $636.4K $957.0K
YoY Change 1568.86% 99.91% -17.9%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.923M $636.4K $2.602M
YoY Change 780.22% 99.91% 29.93%
Operating Profit -$2.923M -$2.602M
YoY Change 780.22% 29.93%
Interest Expense $36.94K -$40.00K $159.9K
YoY Change -192.36% 300.0% -899.43%
% of Operating Profit
Other Income/Expense, Net -$32.89K $0.00 -$234.6K
YoY Change -79.69% 1453.68%
Pretax Income -$2.960M -$1.620M -$2.840M
YoY Change 504.08% 141.79% 40.59%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.955M -$1.617M -$2.836M
YoY Change 498.29% 140.42% 40.59%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$493.3K -$269.6K -$1.198M
COMMON SHARES
Basic Shares Outstanding 6.100M shares 6.097M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2013 Q4 2013
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.84M $24.20M $24.20M
YoY Change 1207.78% 20066.67%
Cash & Equivalents $21.84M $24.20M $24.20M
Short-Term Investments
Other Short-Term Assets $180.0K $230.0K $230.0K
YoY Change
Inventory
Prepaid Expenses $176.2K $234.3K
Receivables
Other Receivables
Total Short-Term Assets $22.01M $24.43M $24.43M
YoY Change 1218.07% 20958.81% 20258.33%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $555.5K $555.5K $560.0K
YoY Change 5455.05%
Total Long-Term Assets $555.5K $555.5K $560.0K
YoY Change 5455.05%
TOTAL ASSETS
Total Short-Term Assets $22.01M $24.43M $24.43M
Total Long-Term Assets $555.5K $555.5K $560.0K
Total Assets $22.57M $24.99M $24.99M
YoY Change 1243.29% 21437.64% 20725.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.120M $280.0K $280.0K
YoY Change 314.81% 180.0%
Accrued Expenses $390.0K $560.0K $560.0K
YoY Change 129.41% 33.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.443M $1.443M $1.440M
YoY Change
Total Short-Term Liabilities $2.944M $2.285M $2.280M
YoY Change 339.39% 300.57% 300.0%
LONG-TERM LIABILITIES
Long-Term Debt $1.157M $1.511M $1.510M
YoY Change -60.66% 54.26% 54.08%
Other Long-Term Liabilities $20.00K $6.830K $10.00K
YoY Change
Total Long-Term Liabilities $1.157M $1.518M $1.520M
YoY Change -60.66% 54.96% 55.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.944M $2.285M $2.280M
Total Long-Term Liabilities $1.157M $1.518M $1.520M
Total Liabilities $4.116M $3.803M $3.800M
YoY Change 14.02% 145.34% 145.16%
SHAREHOLDERS EQUITY
Retained Earnings -$22.69M
YoY Change
Common Stock $610.00 $43.87M
YoY Change 35382745.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.45M $21.18M $21.18M
YoY Change
Total Liabilities & Shareholders Equity $22.57M $24.99M $24.99M
YoY Change 1243.29% 21437.64% 20725.0%

Cashflow Statement

Concept 2014 Q1 2013 Q4 2013
OPERATING ACTIVITIES
Net Income -$2.955M -$1.617M -$2.836M
YoY Change 498.29% 140.42% 40.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.001M -$1.890M -$3.040M
YoY Change 348.07% 190.77% 73.74%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $25.12M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -360.6K 2.350M 27.12M
YoY Change -118.03% 2612.09%
NET CHANGE
Cash From Operating Activities -2.001M -1.890M -3.040M
Cash From Investing Activities
Cash From Financing Activities -360.6K 2.350M 27.12M
Net Change In Cash -2.361M 460.0K 24.08M
YoY Change -251.99% -170.77% -3311.34%
FREE CASH FLOW
Cash From Operating Activities -$2.001M -$1.890M -$3.040M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2007Q4 us-gaap Stockholders Equity
StockholdersEquity
-1922195
CY2014Q1 dei Entity Public Float
EntityPublicFloat
27627705
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6099547 shares
CY2007Q1 us-gaap Stockholders Equity
StockholdersEquity
CY2007Q4 us-gaap Bridge Loan
BridgeLoan
250000
CY2007Q4 us-gaap Interest Receivable
InterestReceivable
42538
CY2007Q4 evok Convertible Preferred Stock Purchased Price Per Share
ConvertiblePreferredStockPurchasedPricePerShare
1.5
CY2008Q4 us-gaap Stockholders Equity
StockholdersEquity
-5133675
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-2401244
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-485904
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
123250 shares
CY2008Q4 evok Convertible Preferred Stock Purchased Price Per Share
ConvertiblePreferredStockPurchasedPricePerShare
1.5
CY2009Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
-10275510
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
-15275792
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4036763
CY2011Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
39000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1242750 shares
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-17654331
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
865876
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1242750 shares
CY2012Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2576252 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.40
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2012Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1000000
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
979792
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
195525
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
367000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
570409
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
417611
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
56000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-19659354
CY2012Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
96798
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
124
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
116013
CY2012Q4 us-gaap Long Term Debt
LongTermDebt
979792
CY2012Q4 us-gaap Liabilities
Liabilities
1550201
CY2012Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Assets Current
AssetsCurrent
116013
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
367000
CY2012Q4 us-gaap Assets
Assets
116013
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116013
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
19855003
CY2012Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
20208
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
578
CY2012Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
26000
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
203000
CY2012Q4 evok Warrant Liability
WarrantLiability
56000
CY2012Q4 evok Working Capital Surplus Deficit
WorkingCapitalSurplusDeficit
-454396
CY2012Q4 evok Deferred Tax Assets Purchased Technology Net
DeferredTaxAssetsPurchasedTechnologyNet
164000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6096752 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
90540 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6096752 shares
CY2013Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1069250 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.61
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
624750 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.61
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1749863
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
624750 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.39
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
93399
CY2013Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2013Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
3000000
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1511461
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43874119
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
169002
CY2013Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
437000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2284906
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
557399
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
21183261
CY2013Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1572285
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
284915
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
6830
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
610
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24986458
CY2013Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1572285
CY2013Q4 us-gaap Long Term Debt
LongTermDebt
2954053
CY2013Q4 us-gaap Liabilities
Liabilities
3803197
CY2013Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
75603
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1442592
CY2013Q4 us-gaap Assets Current
AssetsCurrent
24430953
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
555505
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
234262
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
437000
CY2013Q4 us-gaap Assets
Assets
24986458
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
869490
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24196691
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
931000
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
638881
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
22691468
CY2013Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
8400000
us-gaap Revenue From Grants
RevenueFromGrants
244000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22705
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
555505
evok Change In Fair Value Of Purchase Right Liability
ChangeInFairValueOfPurchaseRightLiability
188587
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
2500000
us-gaap Interest Income Other
InterestIncomeOther
221100
CY2013Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
45947
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
869490
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3055000
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
290000
CY2013Q4 evok Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
23260
CY2013Q4 evok Working Capital Surplus Deficit
WorkingCapitalSurplusDeficit
22146047
CY2013Q4 evok Deferred Tax Assets Purchased Technology Net
DeferredTaxAssetsPurchasedTechnologyNet
147000
CY2013Q4 evok Share Based Compensation Arrangement By Share Based Payment Award Option Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercised
326750 shares
CY2013Q4 evok Debt Instrument Carrying Amount Current
DebtInstrumentCarryingAmountCurrent
1465852
CY2013Q4 evok Debt Instrument Carrying Amount Non Current
DebtInstrumentCarryingAmountNonCurrent
1534148
CY2013Q4 evok Stockholder Equity Reverse Stock Split Effective Date
StockholderEquityReverseStockSplitEffectiveDate
2013-08-30
CY2013Q4 evok Long Term Debt Minimum Payments
LongTermDebtMinimumPayments
3144570
CY2013Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
One-for-five
us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
108486 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22024236
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
234262
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-6830
us-gaap Operating Income Loss
OperatingIncomeLoss
-22547890
us-gaap Interest Paid
InterestPaid
228751
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-143578
us-gaap Net Income Loss
NetIncomeLoss
-22691468
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
292538
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
17744041
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
842314
us-gaap Interest Expense Other
InterestExpenseOther
365827
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
54264
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4949381
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46220927
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
5500000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
18225166
us-gaap Share Based Compensation
ShareBasedCompensation
235677
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
24196691
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25125528
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16948509
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
101358
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
57686
us-gaap Other Noncash Expense
OtherNoncashExpense
129327
us-gaap Operating Expenses
OperatingExpenses
22547890
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
250000
CY2012Q3 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.80 pure
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0233 pure
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
CY2011 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-587848
CY2012Q3 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0143 pure
CY2012Q3 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
CY2013Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P9Y6M
CY2013Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.80 pure
CY2013Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0186 pure
CY2013Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
CY2012Q3 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P10Y
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
4580
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
77358
us-gaap Net Income Loss
NetIncomeLoss
-2009591
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5458
evok Convertible Preferred Stock Issuance Cost
ConvertiblePreferredStockIssuanceCost
218037
evok Estimated Fair Value Of Exercised Purchase Right Per Share
EstimatedFairValueOfExercisedPurchaseRightPerShare
0.04
evok Restricted Common Stock Issued Per Share
RestrictedCommonStockIssuedPerShare
0.005
CY2009 us-gaap Net Income Loss
NetIncomeLoss
-5159638
CY2009 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17803
CY2010 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-5039338
CY2010 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15056
CY2011 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2011 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
-0.439 pure
CY2011 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2011 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.002 pure
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1102625 shares
CY2011 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.001 pure
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.05
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2893108
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.18
CY2011 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.058 pure
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2572252 shares
CY2011 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.042 pure
CY2011 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
140125 shares
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-76353
CY2011 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
277779
CY2011 us-gaap Interest Income Other
InterestIncomeOther
10696
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-2414568
CY2011 us-gaap Interest Paid
InterestPaid
1346
CY2011 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13324
CY2013 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2007-01-29
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001403708
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.79
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1844044
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
12000
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2011 us-gaap Interest Expense Other
InterestExpenseOther
2872
CY2011 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5500
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
570524
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-277779
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
22705
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3170887
CY2011 us-gaap Other Noncash Expense
OtherNoncashExpense
2426
CY2011 us-gaap Operating Expenses
OperatingExpenses
2414568
CY2013 dei Trading Symbol
TradingSymbol
EVOK
CY2013 dei Entity Registrant Name
EntityRegistrantName
Evoke Pharma Inc
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
49000 shares
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
230500 shares
CY2013 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2013 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y
CY2013 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.708 pure
CY2013 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.71 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.021 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M28D
CY2013 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
-0.395 pure
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
7.45
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.025 pure
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2368006 shares
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.39
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.33
CY2013 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0144 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3040270
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.20
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
501500 shares
CY2013 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M2D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.794 pure
CY2013 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2015-12-31
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
24080678
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25120948
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y4M28D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0175 pure
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentrations of Risk</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Financial instruments that potentially subject the Company to significant credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in a federally insured financial institution in excess of federally insured limits. The Company has established guidelines designed to maintain safety and liquidity, has not experienced any losses in such accounts and believes the exposure to significant risk to the cash balance is minimal.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> In addition, the Company relies on third-party manufacturers for the production of its drug candidate. If the third-party manufacturers are unable to continue manufacturing the Company&#x2019;s drug candidate, or if the Company loses one of its sole source suppliers used in its manufacturing processes, the Company may not be able to meet clinical trial supply demand for its product candidate and the development of the product candidate could be materially and adversely affected.</p> </div>
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.058 pure
CY2013 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
2000000
CY2013 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
12.00
CY2013 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
18225166
CY2013 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
144570
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2013 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained.
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
730750 shares
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201C;GAAP&#x201D;). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2013 evok Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueOptionsExercised
CY2013 evok Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted
P9Y10M17D
CY2013 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
470000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.043 pure
CY2013 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
103750 shares
CY2013 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.018 pure
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
234262
CY2013 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-6830
CY2013 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
555505
CY2013 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
2344875
CY2013 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
187000
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
49000
CY2013 us-gaap Interest Income Other
InterestIncomeOther
7248
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-2601828
CY2013 us-gaap Interest Paid
InterestPaid
128875
CY2013 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1514177
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-234637
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-2836465
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
18225166
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
145966
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25120948
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
327905
CY2013 us-gaap Interest Expense Other
InterestExpenseOther
159885
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
82000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1644848
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27120948
CY2013 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
28980000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
956980
CY2013 evok Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Exercised
CY2013 evok Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Options Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueOptionsGranted
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
145966
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2013 evok Minimum Age Of Employee To Participate In Defined Benefit Plan
MinimumAgeOfEmployeeToParticipateInDefinedBenefitPlan
P21Y
CY2012 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
-0.364 pure
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
8886
CY2013 us-gaap Other Noncash Expense
OtherNoncashExpense
23261
CY2013 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
0
CY2013 us-gaap Operating Expenses
OperatingExpenses
2601828
CY2013 evok Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeited
CY2013 evok Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
P3Y
CY2013 evok Cumulative Minimum Change In Ownership Percentage For Limitation On Utilization Of Net Operating Loss Carry Forwards
CumulativeMinimumChangeInOwnershipPercentageForLimitationOnUtilizationOfNetOperatingLossCarryForwards
0.50 pure
CY2013 evok Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Cancelled
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Cancelled
CY2013 evok Offering Cost
OfferingCost
3859052
CY2013 evok Income Tax Examination Period
IncomeTaxExaminationPeriod
Beginning 2007 to date
CY2013 evok Lease Commencement Date
LeaseCommencementDate
December 1, 2013
CY2013 evok Class Of Warrants Or Rights Expiration Date Of Warrant Or Right
ClassOfWarrantsOrRightsExpirationDateOfWarrantOrRight
2022-06-01
CY2008 us-gaap Net Income Loss
NetIncomeLoss
-3227664
CY2008 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16184
CY2008 evok Convertible Preferred Stock Issuance Cost
ConvertiblePreferredStockIssuanceCost
1855
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
215500 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M2D
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
0.40
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.049 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1124000 shares
CY2012 us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
24250 shares
CY2012 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.058 pure
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1165645
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
5000
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2576252 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.015 pure
CY2012 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
118750 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.000 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.00
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-2017528
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12505
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39459
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
218909
CY2012 us-gaap Interest Expense Other
InterestExpenseOther
24042
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
12505
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-749863
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
406862
CY2012 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
24250
CY2012 us-gaap Interest Income Other
InterestIncomeOther
1690
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-2002426
CY2012 us-gaap Interest Paid
InterestPaid
20000
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15102
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7250
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
836781
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1000000
CY2012 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
1000000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2012 us-gaap Other Noncash Expense
OtherNoncashExpense
4042
CY2012 us-gaap Operating Expenses
OperatingExpenses
2002426
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1133375 shares
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-493992
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
221049
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
110981
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1118375 shares
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-500158
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
205137
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
297285
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1122125 shares
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-358666
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
147328
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
213010
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1137125 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-239871
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
72578
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
130846
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1125875 shares
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-486254
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78731
CY2012Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1129625 shares
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.60
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-672450
CY2012Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
343570
CY2012Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
318347
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
140746
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
337003
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1190212 shares
CY2013Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5971236 shares
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2013Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
636423
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-1616698
CY2013Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
944359

Files In Submission

Name View Source Status
0001193125-14-114409-index-headers.html Edgar Link pending
0001193125-14-114409-index.html Edgar Link pending
0001193125-14-114409.txt Edgar Link pending
0001193125-14-114409-xbrl.zip Edgar Link pending
d652766d10k.htm Edgar Link pending
d652766dex1012.htm Edgar Link pending
d652766dex1013.htm Edgar Link pending
d652766dex1015.htm Edgar Link pending
d652766dex231.htm Edgar Link pending
d652766dex311.htm Edgar Link pending
d652766dex312.htm Edgar Link pending
d652766dex321.htm Edgar Link pending
d652766dex322.htm Edgar Link pending
evok-20131231.xml Edgar Link completed
evok-20131231.xsd Edgar Link pending
evok-20131231_cal.xml Edgar Link unprocessable
evok-20131231_def.xml Edgar Link unprocessable
evok-20131231_lab.xml Edgar Link unprocessable
evok-20131231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g652766g25i30_g.jpg Edgar Link pending
g652766g62r40.jpg Edgar Link pending
g652766g65y66.jpg Edgar Link pending
g652766g92e85.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending